Onxeo S.A. buy Letue35
Summary
This prediction ended on 23.05.18 with a price of €1.28. The BUY prediction by Letue35 for Onxeo S.A. performed very badly with a performance of -36.69%. Letue35 has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | -6.114% | -6.114% | -56.727% | -83.472% |
| iShares Core DAX® | -5.630% | -5.765% | 8.425% | 8.571% |
| iShares Nasdaq 100 | -8.559% | -13.005% | 17.297% | 28.853% |
| iShares Nikkei 225® | -9.576% | -9.058% | 3.827% | 0.117% |
| iShares S&P 500 | -6.631% | -7.103% | 17.407% | 31.169% |
Comments by Letue35 for this prediction
In the thread Onxeo S.A. diskutieren
Rebound hoch ploint Jahres
Der Wert rezidivierende nach einem Höhepunkt markiert hat. Es sollte in Kürze zurückkehren